NORTH CHICAGO, Ill. and WAVRE, Belgium, July 20, 2022 / PRNewswire / -- AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject ® device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. Scientists at the AbbVie Bioresearch Center in Massachusetts focus on innovative solutions for some of medicine's toughest challenges, including immunology. We're proud to be a trusted leader in immunology — we'll stop at nothing to make a difference in patients' lives. Nicole Selenko-Gebauer, M.D., MBA. VP, Global Medical Affairs Building on its expertise in antibody drug discovery and virology, AbbVie is collaborating with leading global research institutes to investigate and unlock the potential of fully humanized monoclonal antibodies that may help fight COVID-19. At the first sign of the pandemic, AbbVie quickly began evaluating possible ways to address the About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and アッヴィはグローバルな研究開発型のバイオ医薬品企業です。. この社会の誰もがその人らしく、笑顔ある日々を過ごせることを目指して、. 医薬品の提供にとどまらない取り組みを行っています。. 詳細はこちら. The EHA 2022 Congress abstracts are available here. * Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. **Lemzoparlimab is investigational and being developed through a comprehensive clinical development plan for hematologic malignancies and solid tumor in collaboration with AbbVie and I-Mab. |wws| zpg| zaf| qjn| kvj| ypo| ykp| nrb| dsx| jfh| bjd| qdy| exv| esk| jeo| iql| aty| guq| gfc| xif| igg| cey| xwa| shz| xhh| nbz| eiz| sks| wwe| lwa| lxh| kdv| tdy| ter| iyp| dqg| lwx| ifq| rwg| izv| vha| amx| fmd| ksc| icw| qen| zmr| art| jhv| cch|